Brief: Cardiol - Receives Clearance From FDA, Regulatory Agencies In Brazil, Mexico For Protocol Amendments To Expedite Patient Enrollment In Lancer Trial

Cardiol Therapeutics

01/03/2022 12:45

March 1 (Reuters) - Cardiol Therapeutics Inc  CRDL.TO :
    * CARDIOL - RECEIVES CLEARANCE FROM FDA, REGULATORY AGENCIES
IN
BRAZIL, MEXICO FOR PROTOCOL AMENDMENTS TO EXPEDITE PATIENT
ENROLLMENT IN LANCER TRIAL
    * CARDIOL - LANCER TRIAL EXPANDED TO INCLUDE UP TO 20
ADDITIONAL
CLINICAL RESEARCH CENTERS
    * CARDIOL -  EXPECTS THE LANCER TRIAL TO ACHIEVE COMPLETE
FULL
PATIENT ENROLLMENT DURING THE SECOND HALF OF 2022


 ((Reuters.Briefs@thomsonreuters.com;))